Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23712705 | 0.94 | NR1H2 (0.43) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL26423420 | 0.94 | NR1H2 (0.43) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL14626776 | 0.90 | NR1H2 (0.38) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL14627099 | 0.89 | KMT2A (0.41) | NR1H2SRC | |
| SCHEMBL29007753 | 0.87 | NR1H2 (0.41) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL26423411 | 0.86 | NR1H2 (0.44) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL26423414 | 0.86 | NR1H2 (0.44) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL23712567 | 0.86 | NR1H2 (0.44) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL24739166 | 0.85 | NR1H2 (0.47) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL21770659 | 0.85 | NR1H2 (0.47) | NR1H2SRCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| CN-115698020-B | Macrocyclic RIP 2-kinase inhibitors | 昂科迪塞恩精密医药公司(OPM) | 2025-02-25 | — | — | CN | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| EP-4097110-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | Oncodesign S.A. (FR) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021152165-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | NR1H2 167/4885SRC 3102/4885CHRM2 2228/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | NR1H2 804/4885SRC 2369/4885CHRM2 3874/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | NR1H2 2632/4885SRC 2053/4885CHRM2 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.